## **Anosmia in COVID-19 patients**

- Daniel Hornuss, M.D. <sup>1</sup>, Berit Lange, M.D. <sup>2</sup>, Nils Schröter<sup>3</sup>, M.D., Siegbert Rieg, M.D. <sup>1</sup>, Winfried
- 4 V. Kern, M.D. <sup>1</sup>, Dirk Wagner, M.D. <sup>1\*</sup>
- <sup>1</sup> Section of Infectious Diseases, Department of Internal Medicine II, Medical Center University
- 6 of Freiburg, Faculty of Medicine, University of Freiburg, Germany
- <sup>2</sup> Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germa-
- 8 **ny**

11

16 17 18

24

26

1

2

- <sup>3</sup> Department of Neurology and Neurophysiology, Medical Center University of Freiburg, Facul-
- ty of Medicine, University of Freiburg, Germany
- \* Corresponding author: Dirk Wagner, Section of Infectious Diseases, Department of Internal
- Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg,
- 14 Hugstetter Str. 55, 79106 Freiburg, Germany. Tel. ++49-761-270 18190, Fax ++49-761 270
- 15 18200, email: <u>dirk.wagner@uniklinik-freiburg.de</u>
- 19 Manuscript Word Count: 1041 (of 1200) Research Note
- 20 Abstract Word Count 206 (of 250)
- 21 Reference Number: 10
- 22 Number of Tables: 1
- 23 Number of Figures: 1
- Key words: SARS-CoV-2, COVID-19, Anosmia, Hyposmia, Smelling dysfunction, Sniffin-test

Anosmia in COVID-19 patients - Manuscript - DW

Abstract:

Objectives: Coronaviruses (CoVs) have a neuroinvasive propensity, and the frequently reported symptoms of smelling and taste dysfunction in many COVID-19 patients may be related to the respective capability of SARS-CoV2, the cause of the current pandemic. In this study we objectified and quantified the magnitude and underreporting of the smelling dysfunction caused by COVID-19 using a standardized test.

Methods: We conducted a prospective cross-sectional study comparing the proportion of anosmia using Sniffin-sticks in those reporting a loss of smell, in those who did not as well as in uninfected controls. The outcome of anosmic versus not anosmic patients were recorded during hospital stay and at day 15 on a six-category ordinal scale. The study was approved by the institutional review board, all participants consented to the study.

Results: 40% of 45 consecutive hospitalized COVID-19 patients and 0% of 45 uninfected controls consenting were diagnosed with anosmia. 44% of anosmic and 50% of hyposmic patients did not report having smelling problems. Anosmia or hyposmia was not predictive of a severe COVID-19 manifestation.

Conclusions: The majority of COVID-19 patients have an objective anosmia and hyposmia,

which often occurs unnoticed. These symptoms may be related to the neuroinvasive propensity

of SARS-COV-2 and the unusual presentation of COVID-19 disease manifestations.

Anosmia in COVID-19 patients – Manuscript – DW

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Introduction: Coronaviruses (CoVs) including SARS-CoV-2, the cause of the current pandemic of coronavirus disease 2019 (COVID-19), have a neuroinvasive propensity[1,2], with the olfactorial neurons being currently discussed as portal of entry for neuroinvasion [3] and a spread of CoVs after infection of neural cells from CNS to the periphery via a transneural route [1]. A relevant proportion of admitted COVID-19 patients report the disturbances of taste or smelling [4], without any other obvious cause like nasal obstruction or rhinorrhea, which may be related to this capability. In this study we objectified the magnitude of the smelling disorder caused by SARS-CoV-2.

Methods: Burghart-Sniffin'-Sticks®, a widely used screening test for smelling disorders, was used; according to the manufacturers specifications anosmia, hyposmia and normosmia, were defined as correctly identifying 1-6, 7-10, and 11-12 odors, respectively [5,6]. We conducted a prospective cross-sectional study at the Medical Center - University of Freiburg, Germany in April 2020 comparing the proportion of anosmia in patients with positive PCR result for SARS-CoV-2 in nasopharyngeal swaps or sputum using Sniffin-sticks in those reporting a loss of smell, in those who did not as well as in uninfected patients and health care workers as controls. Patients younger than 18 years, with known smelling disorder or who did not consent to the study were excluded. Assuming a prevalence of anosmia of 5% in the uninfected control group [6], the sample size was calculated to test the null hypothesis that anosmia in COVID-19 is the same as in controls and to find a significant difference using the chi square test with a power of >90%. To compare clinical course (symptoms, laboratory values at the time of the Sniffin test) and outcome of anosmic versus not anosmic patients the worst outcomes during the hospital stay and at day 15 on a six-category ordinal scale (1. discharged; 2. hospitalized, not requiring supplemental oxygen; 3. hospitalized, requiring supplemental oxygen; 4. hospitalized, on (NIV) or high flow oxygen devices; 5. hospitalized, on invasive mechanical ventilation (IMV) or extracorporal membrane oxygenation (ECMO); 6. death) were recorded.

Anosmia in COVID-19 patients - Manuscript - DW

The study was approved by the University hospital ethical committee (No. 184/20), written in-

formed consent was obtained from all participants in the study. Study protocol and data set are

available from the corresponding author upon request.

in patients with and without anosmia or hyposmia (table).

**Results:** We tested 45 consecutive hospitalized COVID-19 patients and 45 uninfected controls (age (median years  $\pm$  STD) 56  $\pm$  16.9 and 54  $\pm$  18.3, respectively) consenting to the study (table). The controls correctly identified a median of 11 out of 12 odors of Sniffin' Sticks, none was anosmic, 12/45 (27%, 95%CI 14-41%, age (median years  $\pm$  STD) 63  $\pm$  19.6) were hyposmic, and 33 (73%, 95%CI 58-85%, age (median years  $\pm$  STD) 49  $\pm$  10.2) were normosmic. A higher percentage (18/45, 40%) of COVID-19 patients were diagnosed with anosmia (p< 0,001; table). COVID-19 patients smell on average 4 sticks less than uninfected controls (figure). The Sniffin' Stick test was more sensitive in detecting anosmia in comparison to self-reporting or taking a medical history: 44% of anosmic and 50% of hyposmic patients did not report having smelling problems. The clinical picture, laboratory test results, and outcome at day 15 or by counting the worst outcome during the hospital stay defined by a rating on a 6-point ordinal scale was similar

*Discussion:* Hyposmia and anosmia are symptoms often noticed by COVID-19 patients [4]. Using a quantitative and objective test almost half of the patients were anosmic, and another 40 % hyposmic. Still in our cohort only 49% of patients reported a smelling dysfunction, which is more than in a recently published survey [4], but significantly less in comparison to what was diagnosed by the Sniffin' test . E.g. the magnitude of the olfactory dysfunction in COVID-patients is underreported with more than 80% of COVID-19 patients having hyposmia or anosmia, in comparison to the uninfected controls, where no participant was anosmic and 27% hyposmic. In a large German community sample (n = 7267) a similar low percentage of anosmia (5%) has been reported using the same test; however the 12-stick-test is not able to distinguish properly between hyposmia and normosmia [6], thus the high percentage of 44 % of our COVID-19 patients with hyposmia needs to be interpreted carefully. Patients were not tested after having

Anosmia in COVID-19 patients – Manuscript – DW

been discharged, but telephone interviews even with patients with mild to moderate COVID-19 showed that not all patients had returned to normal smelling 15 days after start of first symptoms although no other symptoms persisted.

Olfactorial neurons are discussed as portal of entry for neuroinvasion of CoVs which may be transferred to the Central Nervous System (CNS) via a synapse-connected route [2]. It is unclear whether olfactory sensory neurons are directly involved in the pathogenesis of smelling loss in COVID-19, since they have not been shown to coexpress Transmembrane protease, serine 2 (TMPRSS2) and Angiotensin Converting Enzyme 2 (ACE2), which are central for entry of SARS-CoV-2 into human cells [7]. In fact, the detection of the expression of these proteins in coexpression in olfactory sustentacular cells [7] does not preclude the direct involvement of olfacory sensory neurons in COVID-19 associated smelling loss. In a mouse model infected with another human coronavirus, e.g. HCoV-OC43, viral antigen is detected only in the olfactory bulb after 3 and in the whole brain tissue after 7 days [8]. Given the wide distribution of the Angiotensin Converting Enzyme 2 (ACE2)-receptor in the brain [9], the observation that HCoV are able to induce direct neuronal injury within brainstem cardiorespiratory centers in experimental animal models [2] and the increasing evidence that SARS-CoV 2 is also causing neurological complications, the clinical presentation of COVID-19 patients with deterioration at around one week and the acute respiratory failure may be related to the neuroinvasive potential of SARS-CoV-2 [10].

In conclusion all COVID-19 patients should be interviewed and – if possible tested - for olfactory disorders that occur often in COVID-19. Some patients have presented solely with this symptom, e.g. primary physicians and otolaryngologist need to be aware of this putative presentation. Our study shows that anosmia and hyposmia often occurs unnoticed in COVID-19 patients, and that for those patients an objective and quantifiable test is required. Anosmia is not a predictor of a severe COVID-19 manifestation.

Anosmia in COVID-19 patients – Manuscript – DW

Funding: This work was supported by the Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, to NS.

Acknowledgements: We sincerely thank Kamilla Szabo, M.D. and Annegrit Decker, M.D. (Department of Internal Medicine II, Medical Center – University of Freiburg, Germany) for taking care of the patients during the study allowing DH to test the participants.

Reproducible Research Statement: Study protocol and data set: Available from Prof. Dr. D. Wagner (e-mail, dirk.wagner@uniklinik-freiburg.de).

Disclosure: The authors report no disclosures relevant to the manuscript

Anosmia in COVID-19 patients – Manuscript – DW

Legend to Figures:

140

141

142

143

144

145

**Figure: Number of correctly identified odors.** The Sniffin test uses 12 different odors; the percentage of participants (y-axes; COVID-19 patients black bars; controls white bars) correctly identifying the respective number (n, x-axes) of odors is shown. The dashed lines define the cut-

off between anosmia, hyposmia, and normosmia according to the test guidelines [5].

## References

146


178

- [1] Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory
   Virus Infections. Front Cell Neurosci 2018;12:386.
   https://doi.org/10.3389/fncel.2018.00386.
- 150 [2] Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role 151 in the respiratory failure of COVID-19 patients. J Med Virol 2020. 152 https://doi.org/10.1002/jmv.25728.
- Swanson PA, McGavern DB. Viral diseases of the central nervous system. Curr Opin Virol 2015;11:44–54. https://doi.org/10.1016/j.coviro.2014.12.009.
- Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa330.
- Hummel T, Rosenheim K, Konnerth C-G, Kobal G. Screening of Olfactory Function with a 158 Four-Minute Odor Identification Test: Reliability, Normative Data, and Investigations in Pa-159 tients with Olfactory Loss. Ann Otol Rhinol Laryngol 2001;110:976-81. 160 https://doi.org/10.1177/000348940111001015. 161
- [6] Hinz A, Luck T, Riedel-Heller SG, Herzberg PY, Rolffs C, Wirkner K, et al. Olfactory dysfunction: properties of the Sniffin' Sticks Screening 12 test and associations with quality of life. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger
   Soc Oto-Rhino-Laryngol Head Neck Surg 2019;276:389–95. https://doi.org/10.1007/s00405-018-5210-2.
- Fodoulian L, Tuberosa J, Rossier D, Landis B, Carleton A, Rodriguez I. SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium. Neuroscience; 2020. https://doi.org/10.1101/2020.03.31.013268.
- 170 [8] St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ. Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J Virol 2004;78:8824–34. https://doi.org/10.1128/JVI.78.16.8824-8834.2004.
- [9] Kabbani N, Olds JL. Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. Mol Pharmacol 2020;97:351–3. https://doi.org/10.1124/molpharm.120.000014.
- [10] Pérez CA. Looking ahead: The risk of neurologic complications due to COVID-19. Neurol
   Clin Pract 2020:10.1212/CPJ.000000000000836.
   https://doi.org/10.1212/CPJ.000000000000836.

Table: Characteristics and results of COVID-19 patients.

Table. Onaracteristics and results of V		all	with anosmia*	with hyposmia	with normosmia
All (n, %, 95 CI)		45	18 (40%; 25-55%)	20 (44%, 29-60%)	7 (15%, 5-25%)
Sex (n)	female	20	8	8	4
	male	25	10	12	3
Age (median ± STD)	Years	56 ± 16.9	56.5 ± 17.9	58 ± 17.5	49 ± 10.2
Symptoms (n, %)	Temp ≥ 38,5°C	35 (78%)	12 (34%)	16 (46%)	7 (20%)
	Cough	28 (62%)	14 (50%)	10 (36%)	4 (14%)
	Headache	10 (22%)	6 (60%)	4 (40%)	0
	Shortness of Breath	20 (44%)	13 (65%)	5 (25%)	2 (10%)
Laboratory values (mean ± STD) §	Leukocytes (Ths/µI]	5.6 ± 2.8	$6.3 \pm 3.3$	5.5 ±1.9	4.3 ± 3.8
	Lymphocytes (Ths/µI)	1.1 ± 0.7	$0.8 \pm 0.6$	1.1 ± 0.8	$1.4 \pm 0.8$
	CRP (mg/l)	$49 \pm 50$	$60 \pm 42$	46 ±49	19 ± 75
	PCT (ng/ml)	0.12 ± 1.3	$0.13 \pm 0.1$	$0.17 \pm 2.0$	$0.1 \pm 0.1$
	IL6 (pg/ml)	26 ± 44	16 ± 34	27 ± 51	$47 \pm 44$
	LDH (U/I)	284 ± 181	294 ± 258	271 ± 148	249 ± 75
Sniffin Test (median)	correctly identified odors #	8	3	9	11
Report of impaired smelling (n, %, 95Cl) ¶	yes	22 (49%)	10 (45%, 24-68%)	10 (45%, 24-68%)	2 (10%, 1-29%)
	no	23 (51%)	8 (34%, 16-57%)	10 (43%, 23-65%)	5 (21%, 7-43%)
Time course (days; median ± STD)	first symptom to first positive PCR result	2 ± 4.2	2 ± 4.1	1.5 ± 3.7	2 ± 4
	first symptom to reported impaired smelling	5 ± 3.04	$6.5 \pm 3$	$2.5 \pm 2.7$	$5.5 \pm 2.5$
	first symptoms to Sniffin test	10 ± 5.1	11 ± 4	$8.5 \pm 4.5$	12 ± 7.5
	first positive PCR result to Sniffin test	$4 \pm 4.6$	$3.5 \pm 3.9$	4 ± 4.4	$5 \pm 6.3$
Clinical course during hospital stay (n, %) ‡	Discharged	23 (51%)	11 (48%)	9 (39%)	3 (13%)
	No oxygen	,	8 (30%)	13 (48%)	6 (22%)
	Supplemental oxygen	15 (33%)	7 (47%)	7 (47%)	1 (7%)
	NIV or high flow oxygen	2 (4%)	2 (100%)	0	0
	IMV or ECMO	0	0	0	0
	Death	1 (2%)	1 (100%)	0	0
Outcome at day 15 (n, %) †	Discharged	17 (41%)	7 (41%)	6 (35%)	4 (24%)
	No oxygen	14 (32%)	3 (21%)	8 (57%)	3 (21%)
	Supplemental oxygen	9 (22%)	7 (78%)	2 (22%)	0
	NIV or high flow oxygen	0	0	0	0
	IMV or ECMO	0	0	0	0
	Death	1 (2%)	1 (100%)	0	0

COVID-19 patients diagnosed with Sniffin' sticks as normosmic, hyposmic or anosmic (e.g. correctly identifying 11-12, 7-10, and 0-6 odors of Sniffin' sticks, respectively) are shown. n, number; %, percentage; STD, standard deviation; 95%CI, 95% confidence interval; PCR, polymerase chain reaction; NIV = non-invasive ventilation; IMV, invasive mechanical ventilation; ECMO, extracorporal membrane oxygenation. §  $\pm$  2 days from the day of testing, n=33-41. # Linear regression analysis adjusted for age and sex show that COVID-19 patients on average smell 4 sticks less than uninfected controls. ¶ at the day of testing.  $\pm$  the worst outcome was recorded.  $\pm$  n = 41. \*p< 0,001, chi square test with null hypothesis that anosmia in COVID-19 is the same as in controls.



**Correctly identified odors (n)**